Traws Pharma (TRAW) Projected to Post Earnings on Monday

Traws Pharma (NASDAQ:TRAW) is expected to post its Q4 2025 resultson Monday, May 18th. Analysts expect Traws Pharma to post earnings of ($0.5608) per share and revenue of $0.06 million for the quarter. Interested persons may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Wednesday, April 15, 2026 at 4:30 PM ET.

Traws Pharma (NASDAQ:TRAW) last announced its earnings results on Wednesday, April 15th. The company reported ($0.71) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.22) by $0.51. On average, analysts expect Traws Pharma to post $-3 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Traws Pharma Price Performance

TRAW stock opened at $2.18 on Monday. The company’s fifty day simple moving average is $1.66 and its 200 day simple moving average is $1.89. Traws Pharma has a 12-month low of $0.97 and a 12-month high of $3.27. The firm has a market cap of $22.15 million, a price-to-earnings ratio of 2.35 and a beta of 1.47.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on TRAW shares. LADENBURG THALM/SH SH raised shares of Traws Pharma to a “strong-buy” rating in a research report on Friday, January 30th. Weiss Ratings raised shares of Traws Pharma from a “sell (d-)” rating to a “sell (d+)” rating in a research note on Friday, May 1st. One equities research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $8.00.

Insider Activity at Traws Pharma

In other news, major shareholder Orbimed Advisors Llc bought 597,729 shares of the stock in a transaction dated Thursday, April 16th. The shares were bought at an average cost of $1.67 per share, with a total value of $998,207.43. Following the completion of the transaction, the insider directly owned 1,203,250 shares of the company’s stock, valued at $2,009,427.50. This trade represents a 98.71% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 14.00% of the stock is currently owned by corporate insiders.

Institutional Trading of Traws Pharma

A number of hedge funds and other institutional investors have recently bought and sold shares of TRAW. State Street Corp acquired a new position in Traws Pharma during the fourth quarter worth $29,000. Two Sigma Investments LP increased its position in shares of Traws Pharma by 37.1% during the third quarter. Two Sigma Investments LP now owns 22,018 shares of the company’s stock worth $41,000 after acquiring an additional 5,955 shares in the last quarter. XTX Topco Ltd raised its holdings in shares of Traws Pharma by 294.2% in the 4th quarter. XTX Topco Ltd now owns 42,210 shares of the company’s stock worth $48,000 after acquiring an additional 31,502 shares during the last quarter. Geode Capital Management LLC raised its holdings in shares of Traws Pharma by 41.9% in the 4th quarter. Geode Capital Management LLC now owns 61,653 shares of the company’s stock worth $70,000 after acquiring an additional 18,213 shares during the last quarter. Finally, ADAR1 Capital Management LLC bought a new position in Traws Pharma in the 4th quarter valued at about $175,000. Institutional investors own 7.95% of the company’s stock.

About Traws Pharma

Traws Pharma, Inc, a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza.